Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
Research ArticleClinical Investigations

89Zr-Bevacizumab PET Imaging in Primary Breast Cancer

Sietske B.M. Gaykema, Adrienne H. Brouwers, Marjolijn N. Lub-de Hooge, Rick G. Pleijhuis, Hetty Timmer-Bosscha, Linda Pot, Gooitzen M. van Dam, Sibylle B. van der Meulen, Johan R. de Jong, Joost Bart, Jakob de Vries, Liesbeth Jansen, Elisabeth G.E. de Vries and Carolien P. Schröder
Journal of Nuclear Medicine July 2013, 54 (7) 1014-1018; DOI: https://doi.org/10.2967/jnumed.112.117218
Sietske B.M. Gaykema
1Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrienne H. Brouwers
2Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marjolijn N. Lub-de Hooge
2Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands
3Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rick G. Pleijhuis
4Department of Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hetty Timmer-Bosscha
1Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda Pot
1Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gooitzen M. van Dam
4Department of Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sibylle B. van der Meulen
5Department of Radiology, University Medical Center Groningen, Groningen, The Netherlands; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan R. de Jong
2Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joost Bart
6Department of Pathology, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jakob de Vries
4Department of Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liesbeth Jansen
4Department of Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth G.E. de Vries
1Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolien P. Schröder
1Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 54 no. 7 1014-1018
DOI 
https://doi.org/10.2967/jnumed.112.117218
PubMed 
23651946

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication November 26, 2012
  • Accepted for publication January 28, 2013
  • Published online July 1, 2013.

Article Versions

  • previous version (May 7, 2013 - 11:16).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Sietske B.M. Gaykema1,
  2. Adrienne H. Brouwers2,
  3. Marjolijn N. Lub-de Hooge2,3,
  4. Rick G. Pleijhuis4,
  5. Hetty Timmer-Bosscha1,
  6. Linda Pot1,
  7. Gooitzen M. van Dam4,
  8. Sibylle B. van der Meulen5,
  9. Johan R. de Jong2,
  10. Joost Bart6,
  11. Jakob de Vries4,
  12. Liesbeth Jansen4,
  13. Elisabeth G.E. de Vries1 and
  14. Carolien P. Schröder1
  1. 1Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands
  2. 2Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands
  3. 3Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, Groningen, The Netherlands
  4. 4Department of Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands
  5. 5Department of Radiology, University Medical Center Groningen, Groningen, The Netherlands; and
  6. 6Department of Pathology, University Medical Center Groningen, Groningen, The Netherlands
  1. For correspondence or reprints contact: Carolien P. Schröder, Department of Medical Oncology, University Medical Center Groningen, P.O. Box 30001, 9700 RB Groningen; the Netherlands. E-mail: C.P.Schroder{at}umcg.nl
View Full Text

Cited By...

  • 95 Citations
  • Google Scholar

Article usage

Article usage: May 2013 to March 2021

AbstractFullPdf
May 20135020126
Jun 2013149034
Jul 2013157351169
Aug 20133523040
Sep 20132413643
Oct 20131621825
Nov 20131422243
Dec 2013991116
Jan 20141324655
Feb 2014893436
Mar 2014983843
Apr 2014712650
May 2014977248
Jun 2014854241
Jul 2014633335
Aug 2014812220
Sep 20141063834
Oct 2014743328
Nov 2014903740
Dec 2014442223
Jan 2015952528
Feb 20151023427
Mar 20151143423
Apr 20158933035
May 20152043117
Jun 20153014726
Jul 20151813024
Aug 20154182111
Sep 20151074317
Oct 2015772920
Nov 2015744516
Dec 2015883623
Jan 2016832522
Feb 2016732432
Mar 2016391317
Apr 2016342022
May 2016403030
Jun 2016582327
Jul 2016301529
Aug 2016501015
Sep 2016421611
Oct 201633711
Nov 2016411315
Dec 2016281110
Jan 2017562530
Feb 201755168
Mar 2017553522
Apr 201724126
May 2017401111
Jun 2017271013
Jul 20172475
Aug 2017291410
Sep 2017241415
Oct 20172889
Nov 2017261510
Dec 201741169
Jan 20183889
Feb 2018352414
Mar 2018271614
Apr 2018502222
May 201841157
Jun 201839128
Jul 20183167
Aug 20181655
Sep 20183152
Oct 201835142
Nov 2018441312
Dec 20184256
Jan 2019471016
Feb 201953914
Mar 201959712
Apr 2019491019
May 2019281117
Jun 2019251113
Jul 2019342121
Aug 2019271023
Sep 201918715
Oct 2019391820
Nov 201928812
Dec 2019151115
Jan 20201533
Feb 202017710
Mar 202016910
Apr 202014512
May 202015914
Jun 20202298
Jul 202023722
Aug 20202546
Sep 202012610
Oct 202024107
Nov 2020261919
Dec 2020121510
Jan 202172321
Feb 202183424
Mar 202124532
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 54 (7)
Journal of Nuclear Medicine
Vol. 54, Issue 7
July 1, 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
89Zr-Bevacizumab PET Imaging in Primary Breast Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
89Zr-Bevacizumab PET Imaging in Primary Breast Cancer
Sietske B.M. Gaykema, Adrienne H. Brouwers, Marjolijn N. Lub-de Hooge, Rick G. Pleijhuis, Hetty Timmer-Bosscha, Linda Pot, Gooitzen M. van Dam, Sibylle B. van der Meulen, Johan R. de Jong, Joost Bart, Jakob de Vries, Liesbeth Jansen, Elisabeth G.E. de Vries, Carolien P. Schröder
Journal of Nuclear Medicine Jul 2013, 54 (7) 1014-1018; DOI: 10.2967/jnumed.112.117218

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
89Zr-Bevacizumab PET Imaging in Primary Breast Cancer
Sietske B.M. Gaykema, Adrienne H. Brouwers, Marjolijn N. Lub-de Hooge, Rick G. Pleijhuis, Hetty Timmer-Bosscha, Linda Pot, Gooitzen M. van Dam, Sibylle B. van der Meulen, Johan R. de Jong, Joost Bart, Jakob de Vries, Liesbeth Jansen, Elisabeth G.E. de Vries, Carolien P. Schröder
Journal of Nuclear Medicine Jul 2013, 54 (7) 1014-1018; DOI: 10.2967/jnumed.112.117218
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • 89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo
  • 89Zr-oxine labelling and PET imaging shows lung delivery of a cell/gene cancer therapy
  • A Distinct Advantage to Intraarterial Delivery of 89Zr-Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Blood-Brain Barrier
  • Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A
  • PET Imaging of Receptor Tyrosine Kinases in Cancer
  • Tracers for Fluorescence-Guided Surgery: How Elongation of the Polymethine Chain in Cyanine Dyes Alters the Pharmacokinetics of a Dual-Modality c[RGDyK] Tracer
  • Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer
  • 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
  • The Use of Microdosing in the Development of Small Organic and Protein Therapeutics
  • 89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma
  • Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
  • 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease
  • ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment
  • The Use of Novel PET Tracers to Image Breast Cancer Biologic Processes Such as Proliferation, DNA Damage and Repair, and Angiogenesis
  • ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers
  • Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
  • Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer
  • 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment
  • A Modular Labeling Strategy for In Vivo PET and Near-Infrared Fluorescence Imaging of Nanoparticle Tumor Targeting
  • 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
  • Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors
  • Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor
  • Glypican-3-Targeted 89Zr PET Imaging of Hepatocellular Carcinoma: Where Antibody Imaging Dares to Tread
  • CNS Metastases in Breast Cancer: Old Challenge, New Frontiers
  • Google Scholar

More in this TOC Section

  • 18F-FDG Uptake in Less Affected Lung Field Provides Prognostic Stratification in Patients with Interstitial Lung Disease
  • Quantification of Task-Specific Glucose Metabolism with Constant Infusion of 18F-FDG
  • First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
Show more Clinical Investigations

Similar Articles

Keywords

  • Breast cancer
  • VEGF-A
  • 89Zr-bevacizumab PET
  • early detection
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire